Skip to contentC
CytomX Therapeutics, Inc.
C
CTMXCytomX Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$18.66M$18.66M−25.7% vs Q2 2024 Net Income-$154.00K-$154.00KN/M vs Q2 2024 EPS Diluted$0.00$0.00N/M vs Q2 2024 Operating Income-$1,286,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CytomX Therapeutics, Inc. · CIK 1501989 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,780,000N/M Margins · derivedOperating margin-6.9%+26.8 pt vs Q2 2024
Net margin-0.8%+25.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end